Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] <p><strong>As this is the first company under consumer healthcare diagnosis services sector having established brand and has no listed peers to compare with, it may enjoy the benefit of first mover of the sector and hence may attract fancy of investors. Although it being an expensive offer, moderate investment for short to medium term may be considered.</strong></p> Read detail review...
Dr.Lal PathLabs IPO Reviews, analysis and views by popular members. Read Dr.Lal PathLabs Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP